Prudential Financial Inc. increased its position in shares of Fluidigm Co. (NASDAQ:FLDM) by 55.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,950 shares of the medical research company’s stock after buying an additional 5,700 shares during the period. Prudential Financial Inc.’s holdings in Fluidigm were worth $197,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Fluidigm in the second quarter worth $68,000. BNP Paribas Arbitrage SA grew its holdings in Fluidigm by 3,543.1% in the first quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock worth $91,000 after purchasing an additional 6,661 shares during the period. Aperio Group LLC acquired a new stake in Fluidigm in the second quarter worth $124,000. Bank of America Corp DE grew its holdings in Fluidigm by 149.3% in the fourth quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after purchasing an additional 8,654 shares during the period. Finally, SMH Capital Advisors Inc. acquired a new stake in Fluidigm in the first quarter worth $146,000.
In other news, Director Samuel D. Colella purchased 9,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $63,000.00. Following the acquisition, the director now directly owns 115,481 shares of the company’s stock, valued at approximately $808,367. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Levin Easterly Partners Llc sold 186,759 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $12.31, for a total transaction of $2,299,003.29. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 15,000 shares of company stock valued at $95,460 and have sold 1,801,031 shares valued at $16,237,193. Corporate insiders own 2.00% of the company’s stock.
Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 1st. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08). Fluidigm had a negative net margin of 57.48% and a negative return on equity of 31.45%. The firm had revenue of $28.20 million for the quarter, compared to the consensus estimate of $30.16 million. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts predict that Fluidigm Co. will post -0.55 EPS for the current fiscal year.
FLDM has been the subject of a number of research reports. ValuEngine cut shares of Fluidigm from a “buy” rating to a “hold” rating in a report on Wednesday, June 12th. Zacks Investment Research upgraded shares of Fluidigm from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, July 3rd. Finally, BidaskClub cut shares of Fluidigm from a “hold” rating to a “sell” rating in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $14.75.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
See Also: Risk Tolerance
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.